Yahoo! Finance: Top Stories

First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome

Jun 23, 2025 - 10:06
 0
First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
Read More

Tags:

Previous Article

Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.

Next Article

Canaccord Raises Price Target Of Illumina, Inc. (ILMN).

Related Posts

Microsoft Corporation (MSFT): A Bull Case Theory

Microsoft Corporation (MSFT): A Bull Case Theory

May 20, 2025  0

Why Stanley Black & Decker, Inc. (SWK) Soared Today

Why Stanley Black & Decker, Inc. (SWK) Soared Today

May 14, 2025  0

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results

Jefferies Downgrades Prothena Corporation (PRTA) After ...

May 27, 2025  0